In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis | Zendy

Sophie Reissier | Zendy; Azzam Saleh-Mghir | Zendy; François Guérin | Zendy; Laurent Massias | Zendy; Idir Ghout | Zendy; Clara Sinel | Zendy; Vincent Cattoir | Zendy; AnneClaude Crémieux | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vivo daptomycin efficacy against experimental vancomycin-resistant Enterococcus faecium endocarditis

Author(s) -

Sophie Reissier,

Azzam Saleh-Mghir,

François Guérin,

Laurent Massias,

Idir Ghout,

Clara Sinel,

Vincent Cattoir,

AnneClaude Crémieux

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx499

Subject(s) - daptomycin , enterococcus faecium , enterococcus , microbiology and biotechnology , endocarditis , vancomycin , medicine , in vivo , biology , staphylococcus aureus , antibiotics , bacteria , genetics

Daptomycin has become a first-line therapeutic option for vancomycin-resistant Enterococcus faecium infective endocarditis (IE). Although high doses (≥8 mg/kg) are often recommended, optimal doses, particularly for strains with MICs close to the susceptibility breakpoint (4 mg/L), are still debated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research